Showing results (991-1000 of 1,019) with videos related to

Sort By:
Pageof 102
Clinicoeconomics and Outcomes Research : CEOR|April 8, 2024
Willingness to Pay for Social Health Insurance Among Health Care Professionals in North Wollo Zone, Amhara Region, Ethiopia: Mixed Method Study [Retraction]
Clinicoeconomics and Outcomes Research : CEOR|August 28, 2024
Evaluating Service Satisfaction and Sustainability of the Afya Insurance Scheme in Kuwait: An Exploratory AnalysisMaha Alnashmi, Nuzhat Masud Bhuiyan, Nour AlFaham, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 30, 2024
A Mixed-Method Study of Medication-Related Burden Among Multi-Drug Resistant Tuberculosis Patients in West Java, IndonesiaYudisia Ausi, Vycke Yunivita, Prayudi Santoso, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 11, 2024
Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global EvidenceKeyuri Adhikari, Khalid M Kamal, Ki Jin Jeun, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 20, 2024
Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with SchizophreniaChristopher Zacker, Justin T Puckett, Sachin Kamal-Bahl
Clinicoeconomics and Outcomes Research : CEOR|August 12, 2024
Clinical and Economic Impact of Early Diagnosis of Chronic Kidney Disease in General Practice: The Endorse StudyFrancesco Pesce, Giacomo Matteo Bruno, Giorgio Lorenzo Colombo, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 29, 2024
Assessment of Direct Medical Cost of Hospitalized COVID-19 Adult Patients in Kuwait During the First Wave of the PandemicSarah A AlManie, Mai S AlHazami, Alyah Ebrahim, et al.
Clinicoeconomics and Outcomes Research : CEOR|October 3, 2024
Consideration for Health Disparities in Value Assessment FrameworksDominique Seo, Divya Patil, Joe Vandigo, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 1, 2025
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2- Metastatic Breast CancerTimothy J Pluard, Rickard Sandin, Rohan C Parikh, et al.
Clinicoeconomics and Outcomes Research : CEOR|April 21, 2025
A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in ItalyStefano Luminari, Antonio Pinto, Benedetta Puccini, et al.
Pageof 102